Patented Medicine Prices Review Board Will Hear Allegations of Breach of Reporting Requirements for Leukemia Drug
(firmenpresse) - OTTAWA, ONTARIO -- (Marketwired) -- 03/24/16 -- Patented Medicine Prices Review Board
The Patented Medicine Prices Review Board (PMPRB) will hold a public hearing with respect to allegations that Baxalta Canada Corporation failed to provide the PMPRB with the pricing and sales information required by section 80 of the Patent Act and sections 3 and 4 of the Patented Medicine Regulations. The proceeding relates to the medicine Oncaspar, which is sold in Canada under Health Canada''s Special Access Programme and is used in the treatment of patients with Acute Lymphoblastic Leukemia.
The purpose of the hearing is to receive evidence and argument of Board Staff, Baxalta Canada Corporation, and any interveners regarding allegations that Baxalta Canada Corporation is in breach of its reporting requirements. The date, time, and location of the public hearing will be set and confirmed at a later date.
Those wishing to participate in this proceeding must apply to the Board for leave to intervene by May 2, 2016. For more information on the application process, please contact:
Quick Facts
Related Products
Additional Links
Contacts:
Sofie McCoy-Astell
Manager, Communications
Patented Medicine Prices Review Board
613-960-9728
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 24.03.2016 - 15:15 Uhr
Sprache: Deutsch
News-ID 1424022
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
OTTAWA, ONTARIO
Phone:
Kategorie:
National
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 472 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Patented Medicine Prices Review Board Will Hear Allegations of Breach of Reporting Requirements for Leukemia Drug
"
steht unter der journalistisch-redaktionellen Verantwortung von
Patented Medicine Prices Review Board (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
